Annexin-1 is no useful surrogate marker of Multiple Sclerosis - An immunocytochemical study of the cerebrospinal fluid

Clinical Neuropathology

Volumn 30, Issue 1, 2011, Pages 18-24

  Probst Cousin, S ^a   Heuss D ^b   Bergmann, M ^c  

^a KLINIKUM BREMEN OST   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Annexin 1; Cerebrospinal fluid; Immunocytochemistry; Multiple sclerosis; Surrogate markers

Indexed keywords

LIPOCORTIN 1; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; LYME DISEASE; MALE; MULTIPLE SCLEROSIS; NEUROSYPHILIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; VIRUS ENCEPHALITIS; VIRUS MENINGITIS;

ADOLESCENT; ADULT; ANNEXIN A1; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 78751637847     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NPP30018     Document Type: Article

References (22)

1. Bielekova B, Martin R. Development of biomarkers inmultiple sclerosis. Brain. 2004; 127: 1463-1478.
2. Bolton C, Elderfield AJ, Flower RJ. The detection of lipocortins 1, 2 and 5 in central nervous system tissues from Lewis rats with acute experimental allergic encephalomyelitis. J Neuroimmunol. 1990; 29: 173-181.
3. Dreier R, Schmid KW, Gerke V, Riehemann K. Differential expression of annexins I, II and IV in human tissues: An immunohistochemical study.Histochem Cell Biol. 1998; 110: 137-148.
4. Dumont D, Noben J-P, Raus J, Robben J. Proteomic analysis of cerebrospinal fluid frommultiple sclerosis patients. Proteomics. 2004; 4: 2117-2124.
5. Elderfield AJ, Newcombe J, Bolton C, Flower RJ. Lipocortins (annexins) 1, 2, 4 and 5 are increased in the central nervous system in multiple sclerosis. J Neuroimmunol. 1992; 39: 91-100.
6. Flower RJ. Lipocortin and the mechanisms of action of the glucocorticoids. Br. J. Pharmacol. 1988; 94: 987-1015.
7. Flower R J, Rothwell NJ. Lipocortin-1: Cellular mechanisms and clinical relevance. Trends Pharmacol Sci. 1994; 15: 71-76.
8. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol. 2005; 62: 865-870.
9. Gold R, Pepinsky RB, Zettl UK, Toyka KV, Hartung HP. Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. J Neuroimmunol. 1996; 69: 157-164.
10. Goulding NJ, Guyre PM. Glucocorticoids, lipocortins and the immune response. Curr Opin Immunol. 1993; 5: 108-113.
11. Huitinga I, Bauer J, Strijbos PJLM, Rothwell NJ, Dijkstra CD, Tilders FJH. Effect of annexin-1 on experimental autoimmune encephalomyelitis (EAE) in the rat. Clin Exp Immunol.1998; 111: 198-204.
12. Johnson MD, Kamso-Pratt J, Whetsell WO, Pepinsky RB. Lipocortin-1- immunoreactivity in the normal human central nervous system and lesions with astrocytosis. Am J Clin Pathol. 1989; 92: 424-429.
13. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996; 6: 259-274.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, PatyDW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY,Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121-127.
15. Noben J-P, Dumont D, Kwasnikowska N, Verhaert P, Somers V, Hupperts R, Stinissen P, Robben J. Lumbar cerebrospinal fluid proteome in multiple sclerosis: Characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res. 2006; 5: 1647-1657.
16. Perretti M, Flower RJ. Modulation of interleukin- 1 induced neutrophil migration by dexamethasone and lipocortin-1. J Immunol.1993; 150: 992-999.
17. Podgorski MR, Goulding NJ, Hall ND, Flower RJ, Maddison PJ. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis. J Rheumatol. 1992; 19: 1668-1671.
18. Prineas JW, McDonald WI. Demyelinating diseases. In: DI Graham, PI Lantos (eds). Greenfield's Neuropathology, 6th edn, Vol 1. London: Arnold; 1997. p. 813-896.
19. Probst-Cousin S, Kowolik D, Kuchelmeister K, Kayser C, Neundörfer B, Heuss D. Expression of annexin-1 in multiple sclerosis plaques. Neuropathol Appl Neurobiol. 2002; 28: 292-300.
20. Raynal P, Pollard HB. Annexins: The problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochem Biophys Acta. 1994; 1197: 63-73.
21. Rothhut B, Comera C, Prieur B, Errasfa M, MinassianG, Russo Marie F. Purification and characterization of a 32-kDa phospholipase A2 inhibitory protein (lipocortin) from human peripheral blood mononuclear cells. FEBS Lett. 1987; 219: 169-175.
22. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. (Review). N Engl J Med. 1997; 337: 1604-1611.